Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack ® model DF-F non-invasive blood glucose measurement device, announced that Avner Gal, the Company’s Chief Executive Officer, will present at the AMIZINO Fall 2013 Small Cap/Micro Cap Investment Conference at 9:00 a.m. PT on Tuesday, October 29, 2013. The conference will be held at the Sheraton Seattle Hotel, 1400 Sixth Avenue, Seattle, Washington. In his presentation, Mr. Gal will discuss the Company’s CE Marked GlucoTrack ® model DF-F non-invasive glucose monitoring device, designed for spot measuring. GlucoTrack aims to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost and difficulty of conventional spot finger stick devices. About the AMIZINO Fall 2013 Small Cap/Micro Cap Investment Conference This conference is a collaboration between Accredited Members, Inc., a membership-based financial research firm specializing in small cap/micro cap research that hosts 3-4 investment conferences annually, and ZINO Society, a premier membership, business and social network that connects accredited investors with entrepreneurs seeking funding. About Integrity Applications, Inc. Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost, and difficulty of conventional (invasive) spot finger stick devices. Integrity Applications works primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information please visit www.integrity-app.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "will," and "believe," are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity applications to successfully commercialize the GlucoTrack DF-F; the ability of the GlucoTrack DF-F to achieve acceptable pricing, adequate third party reimbursement or market acceptance; the ability of Integrity Applications to manage its growth and the expansion of its operations to include commercialization activities; risks relating to the use of third party manufacturers; risks relating to the development of Integrity Applications’ sales, marketing and distribution capability, either on its own or through collaborations with marketing partners; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012.